Expert Opinion on Pharmacotherapy

Aims & Scope

Expert Opinion on Pharmacotherapy (ISSN 1465-6566 [print], 1744-7666 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.

The Editors welcome: -Reviews covering new drugs/drug classes for specific diseases, from development Phase III to those that have been available to pharmacopoeia for up to 5 years, and their potential impact on future treatment strategies -Drug Evaluations reviewing the clinical and pharmacological data on a particular drug -Original Research papers reporting the results of clinical investigations on agents that are in Phase III and IV clinical trials and pharmacologically based studies with a strong link to clinical practice The audience consists of research and development, regulatory and marketing decision makers in the pharmaceutical industry and decision makers in healthcare provision.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.7
2024	2.50

SJR (SCImago Journal Rank)

Year	Value
2024	0.672

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	99

Journal Rank

Year	Value
2024	8511

Journal Citation Indicator

Year	Value
2024	1443

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Albumin-bound paclitaxel: a next-generation taxane

  Citation: 576

  Authors: William J

• Toxicity of platinum compounds

  Citation: 480

  Authors: Jörg Thomas, Hans-Peter

• Paclitaxel in cancer therapy

  Citation: 315

  Authors: Maurie, Tarek M

• Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review

  Citation: 267

  Authors: Shashank R, Eberhard, Nanwei, Parag, Sanjay, Rahul

• Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management

  Citation: 264

  Authors: Elly, Jorge A, Rebecca E, Tracie L, Steven E

• Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches

  Citation: 255

  Authors: Ilias, Helen

• Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control

  Citation: 253

  Authors: Jürg, Jennifer

• An update on pharmacotherapy for leishmaniasis

  Citation: 246

  Authors: Shyam, Jaya

• Leishmaniasis: an update of current pharmacotherapy

  Citation: 209

  Authors: Shyam, Jaya

• Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study

  Citation: 196

  Authors: Robert, Douglas Y, Akiko, Ilse Van, Christine, Achim, Bernd, Claudia, Mila

---